FDA fast tracks Rx for hard-to-treat peripheral T-cell lymphoma
Allos Therapeutics has received accelerated FDA approval for Folotyn (pralatrexate) as a single-agent treatment in patients with relapsed or refractory peripheral T-cell lymphoma.
Allos Therapeutics has received accelerated FDA approval for Folotyn (pralatrexate) as a single-agent treatment in patients with relapsed or refractory peripheral T-cell lymphoma.
The company's new drug application was based on data from the PROPEL trial, which showed positive results for overall response. Improvement in progression-free survival or overall survival has not been demonstrated, according to Allos. The company will perform more studies to verify the clinical benefit of pralatrexate in T-cell lymphoma.
Articles in this issue
Should surgery dominate as the standard of care for mesothelioma or be in reserve for a select group of pts?
Early study shows promise for radiofrequency ablation in dysplastic Barrett esophagus
ECCO/ESMO study: Endocrine Rx for prostate cancer carries cardiovascular consequences
Measure for measure: How to make practice benchmarks meaningful
Updated regimens on par with standard therapy in diffuse large B-cell lymphoma
Ultrasound targets lymph node recurrence in breast cancer
Experts contest review article declaring breast MRI causes more harm than good by encouraging radical Rx
JAMA article reignites debate over screening
Moving at the speed of science
International trials: Panitumumab delays disease progression in colon cancer mets
Radiation Rx prevents melanoma’s invasion of lymph nodes
Bone marrow aspiration enhances detection of leukemia cells
FDA fast tracks Rx for hard-to-treat peripheral T-cell lymphoma
Infection control wins stimulus funds
Women with small HER2+ breast ca face recurrence risk
Related Videos
Related Content
